Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival.
West Nile virus (WNV) is a mosquito-borne flavivirus that is neurotropic in humans, birds, and other animals. While adaptive immunity plays an important role in preventing WNV spread to the central nervous system (CNS), little is known about how alpha/beta interferon (IFN-alpha/beta) protects against peripheral and CNS infection. In this study, we examine the virulence and tropism of WNV in IFN-alpha/beta receptor-deficient (IFN- alpha/betaR-/-) mice and primary neuronal cultures. IFN-alpha/betaR-/- mice were acutely susceptible to WNV infection through subcutaneous inoculation, with 100% mortality and a mean time to death (MTD) of 4.6 +/- 0.7 and 3.8+/- 0.5 days after infection with 10(0) and 10(2) PFU, respectively. In contrast, congenic wild-type 129Sv/Ev mice infected with 10(2) PFU showed 62% mortality and a MTD of 11.9 +/- 1.9 days. IFN-alpha/betaR-/- mice developed high viral loads by day 3 after infection in nearly all tissues assayed, including many that were not infected in wild-type mice. IFN-alpha/betaR-/- mice also demonstrated altered cellular tropism, with increased infection in macrophages, B cells, and T cells in the spleen. Additionally, treatment of primary wild-type neurons in vitro with IFN-beta either before or after infection increased neuronal survival independent of its effect on WNV replication. Collectively, our data suggest that IFN-alpha/beta controls WNV infection by restricting tropism and viral burden and by preventing death of infected neurons.
Samuel
Melanie A
MA
Department of Molecular Microbiology, Washington University School of Medicine, Campus Box 8051, 660 S. Euclid Ave., St. Louis, MO 63110, USA.
Diamond
Michael S
MS
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology; D001921:Brain / Q000276:immunology / Q000821:virology; D002478:Cells, Cultured; D016898:Interferon-alpha / Q000032:analysis* / Q000172:deficiency / Q000235:genetics / Q000494:pharmacology; D016899:Interferon-beta / Q000032:analysis* / Q000172:deficiency / Q000235:genetics / Q000494:pharmacology; D007372:Interferons / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018482:Muscle, Skeletal / Q000821:virology; D009474:Neurons / Q000187:drug effects / Q000821:virology; D009928:Organ Specificity; D012333:RNA, Messenger / Q000235:genetics; D012337:RNA, Ribosomal, 18S / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013116:Spinal Cord / Q000821:virology; D013154:Spleen / Q000276:immunology / Q000821:virology; D014779:Virus Replication; D014781:Viscera / Q000821:virology; D014901:West Nile Fever / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014902:West Nile virus / Q000502:physiology
D000998:Antiviral Agents; D016898:Interferon-alpha; D012333:RNA, Messenger; D012337:RNA, Ribosomal, 18S; D016899:Interferon-beta; D007372:Interferons